本文選題：HE4 + HMGB1��； 參考：《青島大學(xué)》2014年碩士論文

【摘要】：目的：探討HE4、HMGB1、CA125三種腫瘤標(biāo)志物與上皮性卵巢癌早期診斷及臨床病理特征之間的關(guān)系,以探究三者在上皮性卵巢癌診斷中的意義。 方法：收集150例因卵巢腫物入院手術(shù)的病人,包括上皮性卵巢癌32例、卵巢良性腫瘤79例、卵巢巧克力囊腫患者39例,檢測(cè)其血清HE4、HMGB1、CA125水平,以及45例健康體檢者血清HE4、HMGB1、CA125水平。采用SPSS16.0軟件處理數(shù)據(jù)并制作ROC曲線。 結(jié)果：1.卵巢癌組的血清HE4(198pmol/L)、HMGB1(220.25ug/ml)、CA125(250.5U/mL)均高于健康體檢組、卵巢良性腫瘤組、卵巢巧克力囊腫組。HE4特異性(98.5%)顯著高于CA125(75.3%),敏感性(76.7%)高于CA125(70%),血清HMGB1敏感性較高(78.2%),特異度較低(61.5%)。聯(lián)合檢測(cè)三種標(biāo)志物靈敏度顯著提高,約為95%,特異度接近100%。2.絕經(jīng)前后健康女性及卵巢良性腫瘤患者HE4、HMGB1水平并無(wú)明顯差別,而CA125存在一定差異。而對(duì)于上皮性卵巢癌患者,絕經(jīng)后患者的HE4、HMGB1、CA125水平均較絕經(jīng)前更高。卵巢巧克力囊腫組,未收集到絕經(jīng)后卵巢巧克力囊腫病例。3.卵巢漿液性囊腺癌血清HE4水平最高(約為464.5pmoL/L), CA125水平也最高(約為548.5U/mL),血清HMGB1水平在各種病理分型的卵巢癌間差異無(wú)統(tǒng)計(jì)學(xué)意義(P=0.712)。晚期卵巢癌(包括Ⅲ期、Ⅳ期)血清HE4(264.4pmoL/L)、HMGB1(245.2ug/ml)、CA125(353.6U/mL)高于早期卵巢癌(包括Ⅰ期、Ⅱ期)血清HE4(94.8pmoL/L)、HMGB1(172.8ug/ml)、CA125(86.5U/mL)。三者聯(lián)合檢測(cè)的ROC曲線下面積AUC較單獨(dú)檢測(cè)更大。 結(jié)論：1.聯(lián)合檢測(cè)血清HE4、HMGB1、CA125在早期診斷上皮性卵巢癌的診斷中有更準(zhǔn)確的提示作用。2.聯(lián)合檢測(cè)血清HE4、HMGB1、CA125在區(qū)別卵巢子宮內(nèi)膜異位癥和卵巢惡性腫瘤方面有重要作用。3.血清HE4、HMGB1、CA125水平可以作為評(píng)估卵巢癌患者疾病進(jìn)展及判讀預(yù)后的重要指標(biāo)。
[Abstract]:Objective: to explore the relationship between three tumor markers, early diagnosis and clinicopathological features of epithelial ovarian cancer (EOC) and their significance in the diagnosis of epithelial ovarian cancer (EOC). Methods: the serum levels of HMGB1CA125 in 150 patients with ovarian neoplasms, including 32 epithelial ovarian cancer, 79 benign ovarian tumors and 39 ovarian chocolate cysts, were measured, and the serum levels of HE4HMGB1 and CA125 were measured in 45 healthy controls. SPSS16.0 software is used to process data and make ROC curve. The result is 1: 1. The serum levels of HMGB1) in ovarian cancer group were significantly higher than those in healthy control group (P < 0.05). The specificity of HE4 in ovarian benign tumor group and ovarian chocolate cyst group was significantly higher than that in CA1250.75% (sensitivity 76.7%). The sensitivity of serum HMGB1 was 78.2% and 61.5% higher than that of CA1257.The serum HMGB1 sensitivity of ovarian cancer group was higher than that of CA12570 (P < 0.05), and the sensitivity of serum HMGB1 was significantly higher than that of normal control group (P < 0.05). The sensitivity of serum HMGB1 was significantly higher than that of CA1257.The serum HMGB1 sensitivity was 78.2%, and the specificity was 61.5% higher than that in ovarian benign tumor group. The sensitivity of the combined detection of the three markers was significantly improved, about 95%, and the specificity was close to 100. 2. There was no significant difference in HMGB1 levels between healthy women and patients with benign ovarian tumors before and after menopause, but there was a certain difference in CA125. For epithelial ovarian cancer, the levels of HMGB1 CA125 in postmenopausal patients were higher than those in premenopausal women. Ovarian chocolate cyst group, no postmenopausal ovarian chocolate cyst case. 3. The serum HE4 level of ovarian serous cystadenocarcinoma was the highest (464.5 pmol / L), and the level of CA125 was the highest (about 548.5 U / mL). There was no significant difference in serum HMGB1 level among different pathological types of ovarian cancer. In advanced ovarian cancer (including stage 鈪，

本文編號(hào)：1974373